Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015
A webcast of the presentation will be accessible under Events & Presentations in the Investors section of www.avalanchebiotech.com. Avalanche will maintain an archived replay of the webcast on its website for at least two weeks.
Event
Date:
Time:
Breakfast and Registration:
Program and Webcast:
Guest Speakers
-
Jean Bennett M.D ., Ph.D., Professor, Ophthalmology; Director,Center for Advanced Retinal and Ocular Therapeutics (CAROT),University of Pennsylvania Perelman School of Medicine -
David Brown , M.D.,Retina Consultants ofHouston ; Clinical Professor of Ophthalmology,Baylor College of Medicine -
Jeffrey S. Heier , M.D., Director of Vitreoretinal Service,Ophthalmic Consultants ofBoston -
Szilárd Kiss, M.D., Director of Clinical Research and Associate Professor of Ophthalmology,
Weill Cornell Medical College
About
Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with a clear unmet medical need. Avalanche's proprietary Ocular BioFactory™ is a platform for discovering and developing novel medicines with the potential to offer life-changing therapeutic benefit. Avalanche's lead product candidate, AVA-101, is in mid-stage clinical development for patients with wet age-related macular degeneration. For more information, please visit www.avalanchebiotech.com.
CONTACT: Investor ContactLauren Glaser (650) 656-9347 lauren@avalanchebiotech.com Media ContactCarolyn Wang (415) 946-1065 cwang@w2ogroup.com